The key role of microRNA-766 in the cancer development

Jitendra Gupta; Hussein Riyadh Abdul Kareem Al-Hetty; Murtadha Sh Aswood; Abduladheem Turki Jalil; Maha Dhurgham Azeez; Zafar Aminov; Fahad Alsaikhan; Andrés Alexis Ramírez-Coronel; Pushpamala Ramaiah; Bagher Farhood

doi:10.3389/fonc.2023.1173827

The key role of microRNA-766 in the cancer development

Front Oncol. 2023 May 2:13:1173827. doi: 10.3389/fonc.2023.1173827. eCollection 2023.

Affiliations

¹ Institute of Pharmaceutical Research, GLA University, Mathura, India.
² Department of Nursing, Al-Maarif University College, Ramadi, Anbar, Iraq.
³ Department of Physics, College of Education, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
⁴ Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, Iraq.
⁵ National University of Science and Technology, Dhi Qar, Iraq.
⁶ Department of Public Health and Healthcare management, Samarkand State Medical University, Samarkand, Uzbekistan.
⁷ Department of Scientific Affairs, Tashkent State Dental Institute, Tashkent, Uzbekistan.
⁸ College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
⁹ Azogues Campus Nursing Career, Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Cuenca, Ecuador.
¹⁰ Epidemiology and Biostatistics Research Group, CES University, Medellín, Colombia.
¹¹ Educational Statistics Research Group (GIEE), National University of Education, Azogues, Ecuador.
¹² Faculty of Nursing, Umm al-Qura University, Makkah, Saudi Arabia.
¹³ Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Abstract

Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.

Keywords: biomarker; cancer; drug resistance; miR-766; microRNA.

Publication types

Review